Corrigendum.

Corrigendum. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):552 Authors: PMID: 30037545 [PubMed - in process]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

ConclusionTh17 cells contribute to the stratification of different treatment stages of MM patients. The level of Th17 cells in patients with newly diagnosed MM is associated with the treatment outcome of complete remission.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Bei Xiong, Mei Xue, Yalan Yu, Sanyun Wu, Xuelan ZuoAbstractTo investigate the clinical implications of SF3B1 mutation and ring sideroblasts in myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD), 238 consecutive MDS-RCMD patients were included in this study. Our results showed that SF3B1 mutation in MDS- RCMD patients identifies a distinct subgroup characterized by a high prevalence of erythroid dysplasia and a high proportion of ring sideroblasts, prolonged survival and reduced leukem...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe present analysis identifies disparities in the initial management of older adults with FL owing to race and socioeconomic status. Future research should examine implications for subsequent treatment and health outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study describes the incidence and type of cardiac events (CE) experienced by autologous and allogeneic hematopoietic stem cell transplant patients over a five-year period at one institution. 9.8% of patients experienced a CE, and those that experienced a CE had an increased risk of death within one year (p
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
To investigate the clinical implications of SF3B1 and ring sideroblasts in myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD), 238 consecutive MDS-RCMD patients were included in this study. Our results showed that SF3B1 mutation in MDS- RCMD patients identifies a homogenous phenotype characterized by homogeneous hematologic features including a high prevalence of erythroid dysplasia and a high proportion of ring sideroblasts, prolonged survival and reduced leukemic transformation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ConclusionGenetic abnormalities (FISH/GEP) remain a powerful prognostic indicator for myeloma regardless of MRD status. For newly diagnosed myeloma patients treated with novel triple initial therapy and frontline ASCT, achieving MRD negative status didn’t mitigate poor prognosis outcomes of high-risk MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yenny Alejandra Moreno Vanegas, Ridas Juskevicius, Bhagirathbhai Dholaria
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Megan Melody, Najla Al Ali, Ling Zhang, Hanadi Ramadan, Eric Padron, David Sallman, Kendra Sweet, Jeffrey Lancet, Alan List, John M. Bennett, Rami KomrokjiSummaryBackgroundBone marrow fibrosis (BMF), a poor prognostic factor in myelodysplastic syndromes (MDS), in the context of new risk stratifications of MDS has not been fully explored. Here, we examined the relationship between BMF in MDS and survival outcomes and explored the landscape of somatic gene mutations in the setting of BMF.MethodsWe retrospectively evalua...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsT cell exhaustion has been suspected to contribute to poor persistence of CAR T-cells and clinical relapse, which may be overcome by checkpoint inhibition. While the synergy between CAR T-cell therapy and checkpoint inhibition is promising, the interaction may also lead to off-target irAEs. Prospective trials exploring the safety and efficacy of this combination in relapsed/refractory DLBCL are under way.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Lymphoma | Myeloma